Watchlist Price Alert

Alumis Inc. Common Stock (ALMS)

NASDAQ: ALMS · Real-Time Price · USD

3.13

-0.01 (-0.32%)

At close: Jun 16, 2025, 3:59 PM

3.17

1.28%

After-hours: Jun 16, 2025, 06:48 PM EDT

-0.32% (1D)

Bid	3.05
Market Cap	322.4M
Revenue (ttm)	17.39M
Net Income (ttm)	-343.35M
EPS (ttm)	-10.86
PE Ratio (ttm)	-0.29
Forward PE	-0.94
Analyst	Buy

Ask	3.17
Volume	500,521
Avg. Volume (20D)	1,049,217
Open	3.15
Previous Close	3.14
Day's Range	3.04 - 3.17
52-Week Range	3.04 - 13.53
Beta	-1.90

About ALMS

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol ALMS

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for ALMS stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Why Price Moved

1 month ago

+18.63%

Alumis shares are trading higher after the company... Unlock content with Pro Subscription

2 months ago

+5.82%

Alumis shares are trading higher after the company announced a dermatology collaboration deal with Kaken Pharmaceuticals for ESK-001.

News

2 months ago · businesswire.com

ACELYRIN INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Acelyrin, Inc. - SLRN

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Acelyrin, Inc. (...

2 months ago · marketbeat.com

3 Biopharmaceutical Stocks Bucking the Sell-Off

With tariffs sending markets reeling in the first days of the second quarter—the S&P 500 dropped roughly 10% in the five trading periods through Apr. 7, 2025—investors with cash to spend might be look...